 Home > Medical News > Latest Medical News > Qilu Ruige CDK2/4/6 inhibitor RGT-419B was reported for the first time in China

Qilu Ruige CDK2/4/6 inhibitor RGT-419B was reported for the first time in China

 Last Update: 2022-05-29
 Source: Internet
 Author: User

Tags

journal impact factor

opioid half life

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On February 11, CDE's official website showed that Qilu Ruige's CDK2/4/6 inhibitor RGT-419B was declared for clinical use in China for the first time

RGT-419B is a next-generation CDK2/4/6 small molecule inhibitor with an optimized kinase activity profile

In cell model experiments, RGT-419B showed single-agent activity and greater inhibition of ER+ tumor cell growth than abemaciclib and palbociclib

As a single agent and in combination with other approved therapies, RGT-419B will initially be developed for the treatment of patients with HER2-, ER+ breast cancer who have primary or acquired resistance to currently approved CDK4/6 inhibitors

RGT-419B is the first of many innovative oncology drugs in development by Riage Pharma

HER2-/HR+ breast cancer is the most common type of breast cancer

Regor Therapeutics is a clinical-stage biopharmaceutical high-tech company

Ruige pharmaceutical official website pipeline

However, in early February, Pfizer sued the two founders of Rui Ge Medicine, accusing them of stealing the company's trade secrets while working at Pfizer, arguing that the drug launched by the defendant company was "strikingly similar" to Pfizer, and applied for a patent

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.